Stabilized exendin-4 compounds

a technology of exendin-4 and compound, applied in the direction of peptide/protein ingredients, peptide sources, metabolism disorders, etc., can solve the problem of glp-1's short half-life, and achieve the effects of stable exendin-4 compound and related composition, improved consistency between lots, and more reliable activity
US20090208565A1Inactive Publication Date: 2009-08-20ZEALAND PHARM AS
0 Cites 18 Cited by

Patent Information

Authority / Receiving Office
US · United States
Patent Type
Applications(United States)
Current Assignee / Owner
ZEALAND PHARM AS
Publication Date
2009-08-20
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The present invention discloses compositions comprising a stabilized Exendin-4 (1-39) and related compounds. The invention describes stabilized Exendin-4 agonists that include at least one modified amino acid residue particularly at positions Gln13, Met14, Trp25, or Asn28 of the Exendin-4 (1-39) molecule. Disclosed are preferred modifications of deaminated, hydrolyzed, oxidized, or isomerized reaction products of the specified amino acid residues corresponding to the same positions in the Exendin-4 (1-39) molecule. The invention also relates to methods of making and using the stabilized Exendin compounds, such as for the treatment of diabetes.
Need to check novelty before this filing date? Find Prior Art

Description

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application is a continuation of U.S. application Ser. No. 10 / 529,858, filed Apr. 26, 2006, which is the national phase of International Application No. PCT / DK2003 / 000651, filed Oct. 2, 2003, which, in turn, claims the benefit of U.S. Provisional Application No. 60 / 415,626, filed Oct. 2, 2002. Each of these applications is hereby incorporated by reference.FIELD OF THE INVENTION

[0002] The present invention relates to stabilized Exendin-4 compounds and related molecules. In one aspect the invention provides stabilized Exendin-4 agonists that include at least one modified amino acid residue particularly at positions Gln13, Met14, Trp25, or Asn28 of the Exendin-4 (1-39) molecule. Preferred modifications are deaminated, hydrolyzed, oxidized, or isomerized reaction products of the specified amino acid residues corresponding to the same positions in the Exendin-4 (1-39) molecule. Also provided are methods of making and using the stabilized E...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More